About Amsterdam UMC

Organization

  • World First: First Phase 3 Trial of In Vivo CRISPR Therapy Successfully Completed - CRISPR treatment comes one step closer to reality
    World First: First Phase 3 Trial of In Vivo CRISPR Therapy Successfully Completed - CRISPR treatment comes one step closer to reality Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 study of an in vivo CRISPR therapy. In this large-scale, double-blind Phase 3 trial, 80 patients with hereditary angioedema were randomized to receive either the CRISPR therapy or a placebo. CRISPR therapy is a medical technique that allows doctors to precisely modify errors in cellular DNA to treat specific hereditary diseases. Danny Cohn, leader of the research, is highly enthusiastic: "The study demonstrates that the therapy is genuinely effective and safe. This confirmation is exactly what regulatory authorities need to approve the very first in vivo CRISPR gene editing treatment for the market."
  • Amsterdam UMC gives future generations a seat in Parliament
    Amsterdam UMC gives future generations a seat in Parliament "We must create policy and take action today as if the lives of future generations depend on it. Because they do," says Tessa Roseboom. As the Future Generations Commissioner at Amsterdam UMC, her mission is to make those lives and the interests of future generations audible, visible, and tangible. Today, she symbolically grants them a seat in the House of Representatives’ Committee on Health, Welfare and Sport (VWS) by giving each member a chair and a powerful manifesto.
  • Women with menstrual disorders to receive earlier treatment thanks to major FEMCURE project
    Women with menstrual disorders to receive earlier treatment thanks to major FEMCURE project One in three women experiences menstrual problems due to conditions such as endometriosis, fibroids, or scarring in the uterus. Nevertheless, it often takes 8 to 11 years before they receive a clear diagnosis, and targeted treatments are lacking. The FEMCURE project, led by Professor of Gynaecology Judith Huirne, aims to drastically shorten the time to effective treatment. Researchers will develop self-tests that allow women to assess their symptoms at home. In addition, methods will be devised to help general practitioners and gynaecologists recognize these conditions more quickly. The researchers are also developing targeted therapies, ensuring that each woman receives the treatment most effective for her.

Amsterdam UMC is hiring

We are always on the lookout for talented and passionate people to join our growing team. You will have the opportunity to develop any aspects you are interested in.

See all our vacancies:

Amsterdam UMC is hiring